These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 32864984)
1. Low-Molecular-Weight Heparin and Fondaparinux Use in Pediatric Patients With Obesity. Garner MP; Onuoha CP; Fenn NE Ann Pharmacother; 2021 May; 55(5):666-676. PubMed ID: 32864984 [TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients. Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336 [TBL] [Abstract][Full Text] [Related]
3. Fondaparinux Sodium Compared With Low-Molecular-Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta-analysis. Kumar A; Talwar A; Farley JF; Muzumdar J; Schommer JC; Balkrishnan R; Wu W J Am Heart Assoc; 2019 May; 8(10):e012184. PubMed ID: 31070069 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the Effects of Low-Molecular-Weight Heparin and Fondaparinux on Liver Function in Patients With Pulmonary Embolism. Yang X; Li N; Guo T; Guan X; Tan J; Gao X; Wu Y; Jia L; Gu M; Hua L; Liu H J Clin Pharmacol; 2020 Dec; 60(12):1671-1678. PubMed ID: 32639644 [TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Nutescu EA; Spinler SA; Wittkowsky A; Dager WE Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109 [TBL] [Abstract][Full Text] [Related]
6. Clinical use of low-dose parenteral anticoagulation, incidence of major bleeding and mortality: a multi-centre cohort study using the French national health data system. Bouget J; Balusson F; Kerbrat S; Roy PM; Viglino D; Lacut K; Pavageau L; Oger E Eur J Clin Pharmacol; 2022 Jul; 78(7):1137-1144. PubMed ID: 35385975 [TBL] [Abstract][Full Text] [Related]
7. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin. Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302 [TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080 [TBL] [Abstract][Full Text] [Related]
9. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634 [TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Lim W; Dentali F; Eikelboom JW; Crowther MA Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137 [TBL] [Abstract][Full Text] [Related]
11. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H Cochrane Database Syst Rev; 2011 Feb; (2):CD006649. PubMed ID: 21328285 [TBL] [Abstract][Full Text] [Related]
12. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin. Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321 [TBL] [Abstract][Full Text] [Related]
13. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery. Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444 [TBL] [Abstract][Full Text] [Related]
14. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H Cochrane Database Syst Rev; 2011 Jun; (6):CD006649. PubMed ID: 21678360 [TBL] [Abstract][Full Text] [Related]
15. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis. Thachil J Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488 [TBL] [Abstract][Full Text] [Related]
16. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. O'Brien SH; Kulkarni R; Wallace A; Hamblin F; Burr S; Goldenberg NA J Thromb Haemost; 2014 Nov; 12(11):1822-5. PubMed ID: 25182454 [TBL] [Abstract][Full Text] [Related]
17. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Akl EA; Rohilla S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann HJ Cochrane Database Syst Rev; 2008 Jan; (1):CD006649. PubMed ID: 18254108 [TBL] [Abstract][Full Text] [Related]
18. The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin. Prandoni P; Cattelan AM; Carrozzi L; Leone L; Filippi L; De Gaudenzi E; Villalta S; Pesavento R; Thromb Res; 2020 Dec; 196():395-397. PubMed ID: 33007739 [No Abstract] [Full Text] [Related]
19. Low-molecular-weight heparins in the treatment of deep-vein thrombosis. Martineau P; Tawil N Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481 [TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis. Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]